Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents

Journal of Medicinal Chemistry

Volumn 60, Issue 1, 2017, Pages 170-179

  Cho, Wansang ^a   Koo, Ja Young ^a   Park, Yeonju ^b   Oh, Keunhee ^b   Lee, Sanghee ^a   Song, Jin Sook ^c   Bae, Myung Ae ^c   Lim, Donghyun ^a   Lee, Dong Sup ^b   Park, Seung Bum ^a  

^a Seoul National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; HIGH MOBILITY GROUP B1 PROTEIN; INFLACHROMENE; INTERLEUKIN 6; NITRIC OXIDE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; METABOLIC STABILITY; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; SEPSIS; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; LIVER MICROSOME; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; HMGB1 PROTEIN; INTERLEUKIN-6; MICE; MICROSOMES, LIVER; SEPSIS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85018516878     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00954     Document Type: Article

References (57)

1. Bone, R. C.; Sibbald, W. J.; Sprung, C. L. The ACCP-SCCM Consensus Conference on Sepsis and Organ Failure Chest 1992, 101, 1481-1483 10.1378/chest.101.6.1481
2. Levy, M. M.; Fink, M. P.; Marshall, J. C.; Abraham, E.; Angus, D.; Cook, D.; Cohen, J.; Opal, S. M.; Vincent, J. L.; Ramsay, G. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference Crit. Care Med. 2003, 31, 1250-1256 10.1097/01.CCM.0000050454.01978.3B
3. Deutschman, C. S.; Tracey, K. J. Sepsis: Current Dogma and New Perspectives Immunity 2014, 40, 463-475 10.1016/j.immuni.2014.04.001
4. Takeuchi, O.; Akira, S. Pattern Recognition Receptors and Inflammation Cell 2010, 140, 805-820 10.1016/j.cell.2010.01.022
5. Mogensen, T. H. Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses Clin. Microbiol. Rev. 2009, 22, 240-273 10.1128/CMR.00046-08
6. Rittirsch, D.; Flierl, M. A.; Ward, P. A. Harmful Molecular Mechanisms in Sepsis Nat. Rev. Immunol. 2008, 8, 776-787 10.1038/nri2402
7. Angus, D. C.; van der Poll, T. Severe Sepsis and Septic Shock N. Engl. J. Med. 2013, 369, 840-851 10.1056/NEJMra1208623
8. Angus, D. C.; Linde-Zwirble, W. T.; Lidicker, J.; Clermont, G.; Carcillo, J.; Pinsky, M. R. Epidemiology of Severe Sepsis in the United States: Analysis of Incidence, Outcome, and Associated Costs of Care Crit. Care Med. 2001, 29, 1303-1310 10.1097/00003246-200107000-00002
9. Rangel-Frausto, M. S.; Pittet, D.; Costigan, M.; Hwang, T.; Davis, C. S.; Wenzel, R. P. The Natural History of the Systemic Inflammatory Response Syndrome (SIRS) JAMA 1995, 273, 117-123 10.1001/jama.1995.03520260039030
10. Kaukonen, K.-M.; Bailey, M.; Suzuki, S.; Pilcher, D.; Bellomo, R. Mortality Related to Severe Sepsis and Septic Shock among Critically Ill Patients in Australia and New Zealand, 2000-2012 JAMA 2014, 311, 1308-1316 10.1001/jama.2014.2637
11. Torio, C. M.; Andrews, R. M. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011; U.S. Agency for Health Care Policy and Research: Rockville, MD, 2013.
12. Fink, M. P.; Warren, H. S. Strategies to Improve Drug Development for Sepsis Nat. Rev. Drug Discovery 2014, 13, 741-758 10.1038/nrd4368
13. Ulloa, L.; Tracey, K. J. The “Cytokine Profile”: A Code for Sepsis Trends Mol. Med. 2005, 11, 56-63 10.1016/j.molmed.2004.12.007
14. Ertel, W.; Kremer, J. P.; Kenney, J.; Steckholzer, U.; Jarrar, D.; Trentz, O.; Schildberg, F. W. Downregulation of Proinflammatory Cytokine Release in Whole Blood from Septic Patients Blood 1995, 85, 1341-1347
15. Whang, K. T.; Vath, S. D.; Becker, K. L.; Snider, R. H.; Nylen, E. S.; Muller, B.; Li, Q.; Tamarkin, L.; White, J. C. Procalcitonin and Proinflammatory Cytokine Interactions in Sepsis Shock 2000, 14, 73-78 10.1097/00024382-200014010-00013
16. Bouchon, A.; Facchetti, F.; Weigand, M. A.; Colonna, M. TREM-1 Amplifies Inflammation and Is a Crucial Mediator of Septic Shock Nature 2001, 410, 1103-1107 10.1038/35074114
17. Lorente, J. A.; Marshall, J. C. Neutralization of Tumor Necrosis Factor in Preclinical Models of Sepsis Shock 2005, 24, 107-119 10.1097/01.shk.0000191343.21228.78
18. Alexander, H. R.; Doherty, G. M.; Buresh, C. M.; Venzon, D. J.; Norton, J. A. A Recombinant Human Receptor Antagonist to Interleukin 1 Improves Survival after Lethal Endotoxemia in Mice J. Exp. Med. 1991, 173, 1029-1032 10.1084/jem.173.4.1029
19. Abraham, E.; Laterre, P.-F.; Garbino, J.; Pingleton, S.; Butler, T.; Dugernier, T.; Margolis, B.; Kudsk, K.; Zimmerli, W.; Anderson, P.; Reynaert, M.; Lew, D.; Lesslauer, W.; Passe, S.; Cooper, P.; Burdeska, A.; Modi, M.; Leighton, A.; Salgo, M.; Van der Auwera, P.; Lenercept Study Group Lenercept (p55 Tumor Necrosis Factor Receptor Fusion Protein) in Severe Sepsis and Early Septic Shock: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial with 1,342 Patients Crit. Care Med. 2001, 29, 503-510 10.1097/00003246-200103000-00006
20. Opal, S. M.; Fisher, C. J. J.; Dhainaut, J.-F. A.; Vincent, J.-L.; Brase, R.; Lowry, S. F.; Sadoff, J. C.; Slotman, G. J.; Levy, H.; Balk, R. A.; Shelly, M. P.; Pribble, J. P.; LaBrecque, J. F.; Lookabaugh, J.; Donovan, H.; Dubin, H.; Baughman, R.; Norman, J.; DeMaria, E.; Matzel, K.; Abraham, E.; Seneff, M. Confirmatory Interleukin-1 Receptor Antagonist Trial in Severe Sepsis: A Phase III, Randomized, Doubleblind, Placebo-Controlled, Multicenter Trial Crit. Care Med. 1997, 25, 1115-1124 10.1097/00003246-199707000-00010
21. Kellum, J. A.; Kong, L.; Fink, M. P.; Weissfield, L. A.; Yealy, D. M.; Pinsky, M. R.; Fine, J.; Krichevsky, A.; Delude, R. L.; Angus, D. C.; GenIMS Investigators Understanding the Inflammatory Cytokine Response in Pneumonia and Sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study Arch. Intern. Med. 2007, 167, 1655-1663 10.1001/archinte.167.15.1655
22. Wang, H.; Bloom, O.; Zhang, M.; Vishnubhakat, J. M.; Ombrellino, M.; Che, J.; Frazier, A.; Yang, H.; Ivanova, S.; Borovikova, L.; Manogue, K. R.; Faist, E.; Abraham, E.; Andersson, J.; Andersson, U.; Molina, P. E.; Abumrad, N. N.; Sama, A.; Tracey, K. J. HMG-1 as a Late Mediator of Endotoxin Lethality in Mice Science 1999, 285, 248-251 10.1126/science.285.5425.248
23. Lotze, M. T.; Tracey, K. J. High-Mobility Group Box 1 Protein (HMGB1): Nuclear Weapon in the Immune Arsenal Nat. Rev. Immunol. 2005, 5, 331-342 10.1038/nri1594
24. Yang, H.; Tracey, K. J. Targeting HMGB1 in Inflammation Biochim. Biophys. Acta, Gene Regul. Mech. 2010, 1799, 149-156 10.1016/j.bbagrm.2009.11.019
25. Erlandsson Harris, H.; Andersson, U. Mini-Review: The Nuclear Protein HMGB1 as a Proinflammatory Mediator Eur. J. Immunol. 2004, 34, 1503-1512 10.1002/eji.200424916
26. Sims, G. P.; Rowe, D. C.; Rietdijk, S. T.; Herbst, R.; Coyle, A. J. HMGB1 and RAGE in Inflammation and Cancer Annu. Rev. Immunol. 2010, 28, 367-388 10.1146/annurev.immunol.021908.132603
27. Liu, X.-X.; Wang, C.; Huang, S.-F.; Chen, Q.; Hu, Y.-F.; Zhou, L.; Gu, Y. Regnase-1 in Microglia Negatively Regulates High Mobility Group Box 1-Mediated Inflammation and Neuronal Injury Sci. Rep. 2016, 6, 24073 10.1038/srep24073
28. Rittirsch, D.; Huber-Lang, M. S.; Flierl, M. A.; Ward, P. A. Immunodesign of Experimental Sepsis by Cecal Ligation and Puncture Nat. Protoc. 2008, 4, 31-36 10.1038/nprot.2008.214
29. Hubbard, W. J.; Choudhry, M.; Schwacha, M. G.; Kerby, J. D.; Rue, L. W.; Bland, K. I.; Chaudry, I. H. Cecal Ligation and Puncture Shock 2005, 24, 52-57 10.1097/01.shk.0000191414.94461.7e
30. Yang, H.; Ochani, M.; Li, J.; Qiang, X.; Tanovic, M.; Harris, H. E.; Susarla, S. M.; Ulloa, L.; Wang, H.; DiRaimo, R.; Czura, C. J.; Wang, H.; Roth, J.; Warren, H. S.; Fink, M. P.; Fenton, M. J.; Andersson, U.; Tracey, K. J. Reversing Established Sepsis with Antagonists of Endogenous High-Mobility Group Box 1 Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 296-301 10.1073/pnas.2434651100
31. Wang, H.; Liao, H.; Ochani, M.; Justiniani, M.; Lin, X.; Yang, L.; Al-Abed, Y.; Wang, H.; Metz, C.; Miller, E. J.; Tracey, K. J.; Ulloa, L. Cholinergic Agonists Inhibit HMGB1 Release and Improve Survival in Experimental Sepsis Nat. Med. 2004, 10, 1216-1221 10.1038/nm1124
32. Choi, H. W.; Tian, M.; Song, F.; Venereau, E.; Preti, A.; Park, S.-W.; Hamilton, K.; Swapna, G. V. T.; Manohar, M.; Moreau, M.; Agresti, A.; Gorzanelli, A.; De Marchis, F; Wang, H.; Antonyak, M.; Micikas, R. J.; Gentile, D. R.; Cerione, R. A.; Schroeder, F. C.; Montelione, G. T.; Bianchi, M. E.; Klessig, D. F. Aspirin’s Active Metabolite Salicylic Acid Targets High Mobility Group Box 1 to Modulate Inflammatory Responses Mol. Med. 2015, 21, 526-35 10.2119/molmed.2015.00148
33. Musumeci, D.; Roviello, G. N.; Montesarchio, D. An Overview on HMGB1 Inhibitors as Potential Therapeutic Agents in HMGB1-related Pathologies Pharmacol. Ther. 2014, 141, 347-357 10.1016/j.pharmthera.2013.11.001
34. Wang, H.; Ward, M. F.; Sama, A. E. Targeting HMGB1 in the Treatment of Sepsis Expert Opin. Ther. Targets 2014, 18, 257-268 10.1517/14728222.2014.863876
35. Li, W.; Ashok, M.; Li, J.; Yang, H.; Sama, A. E.; Wang, H. A Major Ingredient of Green Tea Rescues Mice from Lethal Sepsis Partly by Inhibiting HMGB1 PLoS One 2007, 2, e1153 10.1371/journal.pone.0001153
36. Li, W.; Zhu, S.; Li, J.; Assa, A.; Jundoria, A.; Xu, J.; Fan, S.; Eissa, N. T.; Tracey, K. J.; Sama, A. E.; Wang, H. EGCG Stimulates Autophagy and Reduces Cytoplasmic HMGB1 Levels in Endotoxin-Stimulated Macrophages Biochem. Pharmacol. 2011, 81, 1152-1163 10.1016/j.bcp.2011.02.015
37. Kim, J.; Kim, H.; Park, S. B. Privileged Structures: Efficient Chemical “navigators” toward Unexplored Biologically Relevant Chemical Spaces J. Am. Chem. Soc. 2014, 136, 14629-14638 10.1021/ja508343a
38. Zhu, M.; Lim, B. J.; Koh, M.; Park, S. B. Construction of Polyheterocyclic Benzopyran Library with Diverse Core Skeletons through Diversity-Oriented Synthesis Pathway: Part II ACS Comb. Sci. 2012, 14, 124-134 10.1021/co2001907
39. Park, J.; Oh, S.; Park, S. B. Discovery and Target Identification of an Antiproliferative Agent in Live Cells Using Fluorescence Difference in Two-Dimensional Gel Electrophoresis Angew. Chem., Int. Ed. 2012, 51, 5447-5451 10.1002/anie.201200609
40. Lee, S.; Nam, Y.; Koo, J. Y.; Lim, D.; Park, J.; Ock, J.; Kim, J.; Suk, K.; Park, S. B. A Small Molecule Binding HMGB1 and HMGB2 Inhibits Microglia-Mediated Neuroinflammation Nat. Chem. Biol. 2014, 10, 1055-1060 10.1038/nchembio.1669
41. Mosser, D. M.; Edwards, J. P. Exploring the Full Spectrum of Macrophage Activation Nat. Rev. Immunol. 2008, 8, 958-969 10.1038/nri2448
42. Filiano, A. J.; Gadani, S. P.; Kipnis, J. Interactions of Innate and Adaptive Immunity in Brain Development and Function Brain Res. 2015, 1617, 18-27 10.1016/j.brainres.2014.07.050
43. Bonaldi, T.; Talamo, F.; Scaffidi, P.; Bachi, A.; Porto, A.; Rubartelli, A.; Agresti, A.; Bianchi, M. E. Monocytic Cells Hyperacetylate Chromatin Protein HMGB1 to Redirect It towards Secretion EMBO J. 2003, 22, 5551-5560 10.1093/emboj/cdg516
44. Ghosh, M.; Garcia-Castillo, D.; Aguirre, V.; Golshani, R.; Atkins, C. M.; Bramlett, H. M.; Dietrich, W. D.; Pearse, D. D. Proinflammatory Cytokine Regulation of Cyclic AMP-Phosphodiesterase 4 Signaling in Microglia in Vitro and Following CNS Injury Glia 2012, 60, 1839-1859 10.1002/glia.22401
45. Park, B. S.; Song, D. H.; Kim, H. M.; Choi, B.-S.; Lee, H.; Lee, J.-O. The Structural Basis of Lipopolysaccharide Recognition by the TLR4-MD-2 Complex Nature 2009, 458, 1191-1195 10.1038/nature07830
46. Qiao, S.; Luo, Q.; Zhao, Y.; Zhang, X. C.; Huang, Y. Structural Basis for Lipopolysaccharide Insertion in the Bacterial Outer Membrane Nature 2014, 511, 108-111 10.1038/nature13484
47. Dong, H.; Xiang, Q.; Gu, Y.; Wang, Z.; Paterson, N. G.; Stansfeld, P. J.; He, C.; Zhang, Y.; Wang, W.; Dong, C. Structural Basis for Outer Membrane Lipopolysaccharide Insertion Nature 2014, 511, 52-56 10.1038/nature13464
48. Meng, F.; Lowell, C. A. Lipopolysaccharide (LPS)-Induced Macrophage Activation and Signal Transduction in the Absence of Src-Family Kinases Hck, Fgr, and Lyn J. Exp. Med. 1997, 185, 1661-1670 10.1084/jem.185.9.1661
49. Hajishengallis, G.; Lambris, J. D. Microbial Manipulation of Receptor Crosstalk in Innate Immunity Nat. Rev. Immunol. 2011, 11, 187-200 10.1038/nri2918
50. Tsikas, D. Analysis of Nitrite and Nitrate in Biological Fluids by Assays Based on the Griess Reaction: Appraisal of the Griess Reaction in the L-Arginine/nitric Oxide Area of Research J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2007, 851, 51-70 10.1016/j.jchromb.2006.07.054
51. Kawai, T.; Akira, S. Signaling to NF-κB by Toll-like Receptors Trends Mol. Med. 2007, 13, 460-469 10.1016/j.molmed.2007.09.002
52. Zhang, W.; Liu, H. T. MAPK Signal Pathways in the Regulation of Cell Proliferation in Mammalian Cells Cell Res. 2002, 12, 9-18 10.1038/sj.cr.7290105
53. Rao, K. M. K. MAP Kinase Activation in Macrophages J. Leukoc. Biol. 2001, 69, 3-10
54. Oeckinghaus, A.; Hayden, M. S.; Ghosh, S. Crosstalk in NF-κB Signaling Pathways Nat. Immunol. 2011, 12, 695-708 10.1038/ni.2065
55. Avdeef, A.; Berger, C. M.; Brownell, C. pH-Metric Solubility. 2. Correlation Between the Acid-Base Titration and the Saturation Shake-Flask Solubility-pH Methods Pharm. Res. 2000, 17, 85-89 10.1023/A:1007526826979
56. Chang, C. E.; Gilson, M. K. Tork: Conformational Analysis Method for Molecules and Complexes J. Comput. Chem. 2003, 24, 1987-1998 10.1002/jcc.10325
57. Zhu, M.; Kim, M. H.; Lee, S.; Bae, S. J.; Kim, S. H.; Park, S. B. Discovery of Novel Benzopyranyl Tetracycles That Act as Inhibitors of Osteoclastogenesis Induced by Receptor Activator of NF-κB Ligand J. Med. Chem. 2010, 53, 8760-8764 10.1021/jm1011269